På tilbagetrækningstidspunktet var det derfor CHMP' s opfattelse, at fordelene ved Cerepro ikke var tilfredsstillende godtgjort, og at eventuelle fordele ikke opvejede de fundne risici.
Therefore, at the time of the withdrawal, the CHMP’ s view was that a benefit of Cerepro had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.